FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate

Robert F. Kennedy Jr., President-elect Donald Trump’s choice for HHS secretary, is unfit for that role and should not be confirmed, 77 Nobel laureates said in a letter to members of the U.S. Senate.

December 13, 2024

Vol.50 No.46

By Yiqing Wang

Drugs & Targets

FDA approves durvalumab for LS-SCLC

FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

December 13, 2024

Vol.50 No.46

Drugs & Targets

MD Anderson, AmMax Bio announce agreements to develop immunotherapy for MRD-positive cancers

The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Researchers design immunotherapy for glioblastoma

David B. Weiner, of the Wistar Institute, and his laboratory, created a new therapeutic design for glioblastoma, the deadliest form of brain cancer.

December 06, 2024

Vol.50 No.45

Drugs & Targets

FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma

FDA has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for adults

December 06, 2024

Vol.50 No.45

Clinical Roundup

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.

November 22, 2024

Vol.50 No.44

FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

YOU MAY BE INTERESTED IN

Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate

FDA approves durvalumab for LS-SCLC

MD Anderson, AmMax Bio announce agreements to develop immunotherapy for MRD-positive cancers

Researchers design immunotherapy for glioblastoma

FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

Renew today!

Subscriber content

Never miss an issue!

Login